GenEHumDi recommended activities
Events in February 2025
Monday | Tuesday | Wednesday | Thursday | Friday | Saturday | Sunday |
---|---|---|---|---|---|---|
January 27, 2025
|
January 28, 2025
|
January 29, 2025
|
January 30, 2025
|
January 31, 2025
|
February 1, 2025
|
February 2, 2025
|
February 3, 2025
|
February 4, 2025
|
February 5, 2025
|
February 6, 2025
|
February 7, 2025
|
February 8, 2025
|
February 9, 2025
|
February 10, 2025
|
February 11, 2025
|
February 12, 2025
|
February 13, 2025
|
February 14, 2025
|
February 15, 2025
|
February 16, 2025
|
February 17, 2025
|
February 18, 2025
|
February 19, 2025
|
February 20, 2025
|
February 21, 2025
|
February 22, 2025
|
February 23, 2025
|
February 24, 2025
|
February 25, 2025
|
February 26, 2025
|
February 27, 2025
|
February 28, 2025
|
March 1, 2025
|
March 2, 2025
|
Last GenEHumDi Blog entry

2025 Course: Optimizing Gene Editing with Advanced Omics: Safety, Off-Target Detection, and Cell Phenotyping
Read More
Welcome

Welcome to the Genome Editing for the treatment of human Disease Network (GeneHumdi | COST action CA21113) Website. We are Academia and industry scientist, translational scientist, clinicians, regulatory agents, and industry partners dedicated to the improvement and translation of Gene Editing protocols to treat diseases lacking sound medical care or susceptible of increase safety and control of the therapeutic interventions through the implementation of precision gene medicine.
About

Recent advances on genome editing (GE) technologies have opened the possibility of treating diseases through precise modifications of patients’ genomes. Impressive results have been achieved on animal models of several genetic disorders, infectious diseases as well as cancer and several clinical trials are already on going. However, the inadequate integration of the results of academic research into the research development strategy of pharmaceutical companies, the insufficient interest of academic institution in regulatory science and the absence of established standards to well acceptable risk-benefit ratio by regulatory agencies, preclude its general application for treating human diseases. Therefore, the translation of the GE technologies to address public health needs, require a strong collaboration between basic and clinical research, regulatory bodies and the different stake holders involved for each application. There are several networks to improve or analyse GE technologies for different applications, however, no one cover all the actors involved in gene therapy translation.
The principal aim of the GeneHumdi Action is to bring together pharmaceutical companies, academic institution, science and regulatory agencies, biotechnology firms, patient advocacy association and information technology, in order to tackle knowledge fragmentation with the aim to accelerate the translation of GE technologies to the treatment of human diseases. GeneHumdi is supported by COST (European Cooperation in Science and Technology) which is a funding organisation for research and innovation networks operating in Europe since 1971. In their organigram, GeneHumdi nourishes from the ideas exchange of Management Committee (MC) members from over 24 EU Countries and MC and other members are organized into Working Groups (WG) to distribute GeneHumdi workload and allocate specific question to dedicated experts in each field.
Contact
Action Contacts:
COST Staff:
Leadership:
Role | Leader | Phone | |
---|---|---|---|
Action Chair | Dr karim BENABDELLAH | 0034958 715 500 | karim.benabdel@genyo.es |
Action Vice Chair | Dr Alessia CAVAZZA | 02079052787 | a.cavazza@ucl.ac.uk |
Grant Holder Scientific Representative | Dr karim BENABDELLAH | 0034958 715 500 | karim.benabdel@genyo.es |
Science Communication Coordinator | Dr Fco. Javier MOLINA ESTEVEZ | +34623069770 | javier.molina@genyo.es |
Grant Awarding Coordinator | Dr Paula RIO | 0034913460890 | paula.rio@ciemat.es |
WG2 Leader | Dr Rasmus BAK | +45 93929100 | bak@biomed.au.dk |
WG3 Leader | Dr Yonglun LUO | +4587168394 | alun@biomed.au.dk |
WG4 Leader | Dr Ayal HENDEL | 035317316 | ayal.hendel@biu.ac.il |
WG5 Leader | Dr Alessia CAVAZZA | 02079052787 | a.cavazza@ucl.ac.uk |
WG6 Leader | Dr Carsten Werner LEDERER | 22392764 | Lederer@cing.ac.cy |
WG7 Leader | Dr Fco. Javier MOLINA ESTEVEZ | + 34 623069770 | javier.molina@genyo.es |
Additional roles:
Role | Leader | Phone | |
---|---|---|---|
WG2: Improvement of GE technologies Co-Leader | Dr Francisco MARTIN | +34 665287238 | francisco.martin@genyo.es |
WG6: Technological transfer and industry Co-Leader | Dr Monika PAULE | +37060611496 | monika@caszyme.com |
ITC Coordinator | Prof Merita XHETANI | +355672059369 | merita.xhetani@fshn.edu.al |
WG3: Delivery strategies Co-Leader | Dr karim BENABDELLAH | 0034958 715 500 | karim.benabdel@genyo.es |
WG4: Safety issues: Monitoring and standardization Co-Leader | Dr Giandomenico TURCHIANO | 02039783664 | g.turchiano@ucl.ac.uk |
WG5: Translation into the clinic Co-Leader | Dr Paula RIO | 0034913460890 | paula.rio@ciemat.es |
WG6: Technological transfer and industry Co-Leader | Dr philippe DUCHATEAU | 0181691600 | philippe.duchateau@cellectis.com |
WG6: Regulatory Issues Co-Leader | Prof Zoltan IVICS | +496103776000 | zoltan.ivics@pei.de |
International Advisor | Dr Marcello MARESCA | 0046(0)706315840 | Marcello.Maresca@astrazeneca.com |